文献速递性腺与生殖内分泌垂体与肾上腺疾病

睾酮对47,XXY婴儿短期体格、激素及神经发育结局的影响(TESTO研究)

Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该双盲随机对照试验纳入71例30至90日龄经产前诊断的非嵌合型47,XXY婴儿,给予睾酮环丙酸酯25 mg每4周肌内注射共3次,评估12周时体脂百分比z评分与Alberta婴儿运动量表总分百分位变化。睾酮组瘦体重增加更多,但抑制了促性腺激素和抑制素B,神经发育结局无显著组间差异。结果不支持对47,XXY婴儿常规使用睾酮治疗。

要点

  • 睾酮组体脂百分比z评分变化较对照组低0.57(95%CI -1.1至-0.06;P=0.03)。
  • 睾酮组瘦体重增加1.5±0.4 kg,对照组增加1.2±0.4 kg(P=0.001)。
  • 睾酮抑制促性腺激素和抑制素B(P<0.001),神经发育结局无显著组间差异(P>0.15)。

核心结论

  • 在47,XXY婴儿中,睾酮注射产生了可归因于全身雄激素暴露的体格效应,但该剂量抑制了下丘脑-垂体-性腺轴,且未影响神经发育结局。
  • 这些结果不支持对47,XXY婴儿常规使用睾酮治疗,但需要对体格健康、神经发育和睾丸功能进行长期随访。

研究设计与样本

  • 双盲随机对照试验,2017年至2021年在美国一家三级儿科医院开展。
  • 纳入71例30至90日龄经产前诊断的非嵌合型47,XXY婴儿。
  • 干预为睾酮环丙酸酯25 mg每4周肌内注射一次,共3次。
  • 主要结局为从基线至12周体脂百分比z评分变化和Alberta婴儿运动量表总分百分位变化。

主要发现

  • 体脂百分比z评分变化的组间差异为-0.57(95%CI -1.1至-0.06;P=0.03)。
  • 睾酮组瘦体重增加1.5±0.4 kg,对照组增加1.2±0.4 kg(P=0.001)。
  • 睾酮抑制促性腺激素和抑制素B(P<0.001)。
  • 短期运动、认知或语言结局无显著组间差异(P>0.15)。

临床怎么用

  • 原文结论指出这些结果不支持对47,XXY婴儿常规使用睾酮治疗。

局限性

  • 需要对体格健康、神经发育和睾丸功能进行长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: 47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the minipuberty period of infancy. OBJECTIVE: We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY. DESIGN: Double-blind randomized controlled trial, 2017-2021. SETTING: US tertiary care pediatric hospital. PATIENTS: Infants 30 to 90 days of age with prenatally identified, nonmosaic 47,XXY (n = 71). INTERVENTION: Testosterone cypionate 25 mg IM injections every 4 weeks for 3 doses. MAIN OUTCOME MEASURES: The a priori primary outcomes were change in percent fat mass z-scores and change in the total composite percentile on Alberta Infant Motor Scales assessment from baseline to 12 weeks. RESULTS: The between-group difference in change in percent fat mass z-scores was -0.57 (95% CI, -1.1 to -0.06; P = .03), secondary to greater increases in lean mass in the testosterone-treated group (1.5 ± 0.4 kg vs 1.2 ± 0.4; P = .001). Testosterone suppressed gonadotropins and inhibin B (P < .001 for all). In contrast, there were no significant group differences in short-term motor, cognitive, or language outcomes (P > .15 for all). CONCLUSIONS: In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure; however, this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY; however, long-term follow-up on physical health, neurodevelopment, and testicular function is needed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Davis SM, Howell S, Janusz J, et al. Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY. J Clin Endocrinol Metab. 2025. PMID: 40177735. doi:10.1210/clinem/dgaf217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。